Agile Therapeutics (NASDAQ:AGRX) Coverage Initiated by Analysts at StockNews.com

Research analysts at StockNews.com began coverage on shares of Agile Therapeutics (NASDAQ:AGRX) in a note issued to investors on Saturday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.

Separately, Maxim Group reiterated a “hold” rating on shares of Agile Therapeutics in a research note on Monday, March 18th.

Agile Therapeutics Stock Performance

Shares of AGRX opened at $0.38 on Friday. The firm has a market cap of $2.61 million, a P/E ratio of -0.04 and a beta of 1.42. Agile Therapeutics has a fifty-two week low of $0.20 and a fifty-two week high of $7.00. The business has a 50-day moving average of $0.64 and a 200 day moving average of $1.44.

Institutional Trading of Agile Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. increased its holdings in Agile Therapeutics by 1.1% during the 1st quarter. BlackRock Inc. now owns 1,523,758 shares of the specialty pharmaceutical company’s stock worth $319,000 after acquiring an additional 16,104 shares during the period. Renaissance Technologies LLC grew its position in shares of Agile Therapeutics by 281.3% during the 1st quarter. Renaissance Technologies LLC now owns 621,200 shares of the specialty pharmaceutical company’s stock valued at $130,000 after purchasing an additional 458,300 shares in the last quarter. Jane Street Group LLC bought a new position in shares of Agile Therapeutics in the second quarter worth $108,000. Vanguard Group Inc. bought a new position in shares of Agile Therapeutics in the fourth quarter worth $40,000. Finally, Virtu Financial LLC purchased a new stake in shares of Agile Therapeutics in the fourth quarter worth $32,000. 10.92% of the stock is currently owned by institutional investors.

Agile Therapeutics Company Profile

Agile Therapeutics, Inc, a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.